PIRS Share Price | Pieris Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: What does Pieris Pharmaceuticals, Inc. do?

Overview:Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, with a market capitalization of USD 238.34 million.Financial Snapshot:Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025) Market cap: USD 238.34 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.36 Return on Equity: -30.71% Price to Book: 4.29Contact Details:Address: 255 STATE STREET, 9TH FLOOR, BOSTON MA : 02109 Tel: ['1 857 2468998', '1 857 3629635'] Fax: 49 8161 1411444 Website: https://www.pieris.com/

Q: Is Pieris Pharmaceuticals, Inc. overvalued or undervalued?

As of 15 May 2025, Pieris Pharmaceuticals, Inc. has moved from a valuation grade of risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently overvalued, with a price-to-book ratio of 5.13 and a negative return on equity (ROE) of -30.71%. Additionally, the EV to EBITDA ratio stands at -12.36, reflecting ongoing losses and a lack of profitability.In comparison to its peers, Pieris Pharmaceuticals shows a stark contrast, as companies like Elevation Oncology, Inc. and Enlivex Therapeutics Ltd. also do not qualify but have less severe valuations with EV to EBITDA ratios of 0.5869 and -0.2828, respectively. The company's stock performance has been volatile, with a year-to-date return of 87.83%, which, while impressive, is overshadowed by a 3-year decline of -84.93% compared to the S&P 500's 58.74% return in the same period. This further emphasizes the overvaluation of Pieris Pharmaceuticals in the current market context.

Q: Is Pieris Pharmaceuticals, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for Pieris Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and KST. Daily moving averages also indicate a bullish stance. However, the monthly RSI shows a bearish signal, and both the weekly and monthly Dow Theory are mildly bullish. In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 392.00% compared to the S&P 500's 12.22%, and over the past year, it has returned 265.35% against the S&P 500's 17.14%. Overall, the current technical stance is bullish with strong momentum indicators, despite some mixed signals on the monthly timeframe.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

90.49 k

Shareholding (Mar 2025)

FII

0.72%

Held by 8 FIIs

DII

79.45%

Held by 3 DIIs

Promoter

17.11%

How big is Pieris Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Pieris Pharmaceuticals, Inc. has a market capitalization of 238.34 million and reported net sales of 0.00 million with a net profit of -17.21 million over the latest four quarters. Shareholder's funds are 62.61 million, and total assets amount to 88.23 million.

View full answer

What does Pieris Pharmaceuticals, Inc. do?

22-Jun-2025

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company with a market cap of USD 238.34 million, focused on developing innovative therapies. As of March 2025, it reported a net profit loss of USD 8 million and has no dividend yield.

View full answer

Who are in the management team of Pieris Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Pieris Pharmaceuticals, Inc. includes Mr. James Geraghty (Independent Chairman), Mr. Stephen Yoder (President and CEO), and several Independent Directors: Dr. Ann Barbier, Dr. Peter Kiener, Mr. Christopher Kiritsy, Mr. Michael Richman, and Dr. Maya Said.

View full answer

Is Pieris Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of May 15, 2025, Pieris Pharmaceuticals, Inc. is considered overvalued with a price-to-book ratio of 5.13 and a negative return on equity of -30.71%, reflecting significant financial concerns and a stark contrast to its peers, despite a year-to-date stock return of 87.83% overshadowed by a three-year decline of -84.93%.

View full answer

Is Pieris Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Pieris Pharmaceuticals, Inc. shows a bullish technical trend with strong momentum indicators, despite mixed monthly signals, having outperformed the S&P 500 significantly year-to-date and over the past year.

View full answer

Compare Pieris Pharmaceuticals, Inc. with Similar Stocks

Elevation Oncology, Inc.Coeptis Therapeutics Holdings, Inc.Enlivex Therapeutics Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 625 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.17

Return on Equity

-50.10%

Price to Book

13.08

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-9 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

1.83%

6 Months

105.46%

1 Year

450.25%

2 Years

424.93%

3 Years

4076.5%

4 Years

-72.55%

5 Years

-66.94%

Pieris Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-4.40%

EBIT to Interest (avg)

-30.69

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.36

Sales to Capital Employed (avg)

0.94

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

49.46%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.13

EV to EBIT

-12.36

EV to EBITDA

-12.36

EV to Capital Employed

-10.44

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-30.71%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 6 Schemes (2.73%)

Foreign Institutions

Held by 8 Foreign Institutions (0.72%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -15.85% vs -182.76% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.30",
          "val2": "-7.90",
          "chgp": "-17.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "1.20",
          "chgp": "16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.50",
          "val2": "-8.20",
          "chgp": "-15.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -193.05% vs 156.16% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.10",
          "val2": "-11.90",
          "chgp": "-18.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.50",
          "val2": "23.60",
          "chgp": "-106.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.40",
          "val2": "18.70",
          "chgp": "-193.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.30

-7.90

-17.72%

Interest

1.40

1.20

16.67%

Exceptional Items

-0.10

Consolidate Net Profit

-9.50

-8.20

-15.85%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -15.85% vs -182.76% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.10

-11.90

-18.49%

Interest

4.30

0.00

Exceptional Items

-1.50

23.60

-106.36%

Consolidate Net Profit

-17.40

18.70

-193.05%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -193.05% vs 156.16% in Dec 2023

All Annual Results

Company CV

About Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Company Coordinates

Company Details

255 STATE STREET, 9TH FLOOR , BOSTON MA : 02109

Tel: 1 857 24689981 857 3629635

https://www.pieris.com/

Registrar Details

Pieris Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Pieris Pharmaceuticals, Inc.?

Watch in Real-Time

What does Pieris Pharmaceuticals, Inc. do?

Who are in the management team of Pieris Pharmaceuticals, Inc.?

Is Pieris Pharmaceuticals, Inc. overvalued or undervalued?

Is Pieris Pharmaceuticals, Inc. technically bullish or bearish?

Compare Pieris Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Pieris Pharmaceuticals, Inc.

Company Coordinates